These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 28115513)

  • 1. Proton Pump Inhibitors Decrease Soluble fms-Like Tyrosine Kinase-1 and Soluble Endoglin Secretion, Decrease Hypertension, and Rescue Endothelial Dysfunction.
    Onda K; Tong S; Beard S; Binder N; Muto M; Senadheera SN; Parry L; Dilworth M; Renshall L; Brownfoot F; Hastie R; Tuohey L; Palmer K; Hirano T; Ikawa M; Kaitu'u-Lino T; Hannan NJ
    Hypertension; 2017 Mar; 69(3):457-468. PubMed ID: 28115513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.
    Brownfoot FC; Hastie R; Hannan NJ; Cannon P; Tuohey L; Parry LJ; Senadheera S; Illanes SE; Kaitu'u-Lino TJ; Tong S
    Am J Obstet Gynecol; 2016 Mar; 214(3):356.e1-356.e15. PubMed ID: 26721779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low Soluble Fms-Like Tyrosine Kinase-1, Endoglin, and Endothelin-1 Levels in Women With Confirmed or Suspected Preeclampsia Using Proton Pump Inhibitors.
    Saleh L; Samantar R; Garrelds IM; van den Meiracker AH; Visser W; Danser AHJ
    Hypertension; 2017 Sep; 70(3):594-600. PubMed ID: 28716993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Pravastatin on Human Placenta, Endothelium, and Women With Severe Preeclampsia.
    Brownfoot FC; Tong S; Hannan NJ; Binder NK; Walker SP; Cannon P; Hastie R; Onda K; Kaitu'u-Lino TJ
    Hypertension; 2015 Sep; 66(3):687-97; discussion 445. PubMed ID: 26222708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Procyanidin B2 ameliorates endothelial dysfunction and impaired angiogenesis via the Nrf2/PPARγ/sFlt-1 axis in preeclampsia.
    Liu L; Wang R; Xu R; Chu Y; Gu W
    Pharmacol Res; 2022 Mar; 177():106127. PubMed ID: 35150862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining metformin and esomeprazole is additive in reducing sFlt-1 secretion and decreasing endothelial dysfunction - implications for treating preeclampsia.
    Kaitu'u-Lino TJ; Brownfoot FC; Beard S; Cannon P; Hastie R; Nguyen TV; Binder NK; Tong S; Hannan NJ
    PLoS One; 2018; 13(2):e0188845. PubMed ID: 29466360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta.
    Brownfoot FC; Tong S; Hannan NJ; Hastie R; Cannon P; Kaitu'u-Lino TJ
    BMC Pregnancy Childbirth; 2016 May; 16():117. PubMed ID: 27207105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sofalcone upregulates the nuclear factor (erythroid-derived 2)-like 2/heme oxygenase-1 pathway, reduces soluble fms-like tyrosine kinase-1, and quenches endothelial dysfunction: potential therapeutic for preeclampsia.
    Onda K; Tong S; Nakahara A; Kondo M; Monchusho H; Hirano T; Kaitu'u-Lino T; Beard S; Binder N; Tuohey L; Brownfoot F; Hannan NJ
    Hypertension; 2015 Apr; 65(4):855-62. PubMed ID: 25667213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction - implications as a preeclampsia treatment.
    Hannan NJ; Brownfoot FC; Cannon P; Deo M; Beard S; Nguyen TV; Palmer KR; Tong S; Kaitu'u-Lino TJ
    Sci Rep; 2017 May; 7(1):1819. PubMed ID: 28500309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sulfasalazine reduces placental secretion of antiangiogenic factors, up-regulates the secretion of placental growth factor and rescues endothelial dysfunction.
    Brownfoot FC; Hannan NJ; Cannon P; Nguyen V; Hastie R; Parry LJ; Senadheera S; Tuohey L; Tong S; Kaitu'u-Lino TJ
    EBioMedicine; 2019 Mar; 41():636-648. PubMed ID: 30824385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heme Oxygenase-1 Is Not Decreased in Preeclamptic Placenta and Does Not Negatively Regulate Placental Soluble fms-Like Tyrosine Kinase-1 or Soluble Endoglin Secretion.
    Tong S; Kaitu'u-Lino TJ; Onda K; Beard S; Hastie R; Binder NK; Cluver C; Tuohey L; Whitehead C; Brownfoot F; De Silva M; Hannan NJ
    Hypertension; 2015 Nov; 66(5):1073-81. PubMed ID: 26324507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melatonin enhances antioxidant molecules in the placenta, reduces secretion of soluble fms-like tyrosine kinase 1 (sFLT) from primary trophoblast but does not rescue endothelial dysfunction: An evaluation of its potential to treat preeclampsia.
    Hannan NJ; Binder NK; Beard S; Nguyen TV; Kaitu'u-Lino TJ; Tong S
    PLoS One; 2018; 13(4):e0187082. PubMed ID: 29641523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activating Transcription Factor 3 Is Reduced in Preeclamptic Placentas and Negatively Regulates sFlt-1 (Soluble fms-Like Tyrosine Kinase 1), Soluble Endoglin, and Proinflammatory Cytokines in Placenta.
    Kaitu'u-Lino TJ; Brownfoot FC; Hastie R; Chand A; Cannon P; Deo M; Tuohey L; Whitehead C; Hannan NJ; Tong S
    Hypertension; 2017 Nov; 70(5):1014-1024. PubMed ID: 28947613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR (Epidermal Growth Factor Receptor) Signaling and the Mitochondria Regulate sFlt-1 (Soluble FMS-Like Tyrosine Kinase-1) Secretion.
    Hastie R; Brownfoot FC; Pritchard N; Hannan NJ; Cannon P; Nguyen V; Palmer K; Beard S; Tong S; Kaitu'u-Lino TJ
    Hypertension; 2019 Mar; 73(3):659-670. PubMed ID: 30636550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining metformin and sulfasalazine additively reduces the secretion of antiangiogenic factors from the placenta: Implications for the treatment of preeclampsia.
    Brownfoot FC; Hastie R; Hannan NJ; Cannon P; Nguyen TV; Tuohey L; Cluver C; Tong S; Kaitu'u-Lino TJ
    Placenta; 2020 Jun; 95():78-83. PubMed ID: 32452405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disulfiram inhibits placental soluble FMS-like tyrosine kinase-1 and soluble endoglin secretion independent of the proteasome.
    Hastie R; Ye L; Hannan NJ; Brownfoot FC; Cannon P; Nguyen V; Tong S; Kaitu'u-Lino TJ
    Pregnancy Hypertens; 2018 Oct; 14():125-130. PubMed ID: 30527099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Placental-Specific sFLT-1 e15a Protein Is Increased in Preeclampsia, Antagonizes Vascular Endothelial Growth Factor Signaling, and Has Antiangiogenic Activity.
    Palmer KR; Kaitu'u-Lino TJ; Hastie R; Hannan NJ; Ye L; Binder N; Cannon P; Tuohey L; Johns TG; Shub A; Tong S
    Hypertension; 2015 Dec; 66(6):1251-9. PubMed ID: 26416849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: A possible therapeutic for preeclampsia.
    Brownfoot FC; Tong S; Hannan NJ; Hastie R; Cannon P; Tuohey L; Kaitu'u-Lino TJ
    Mol Cell Endocrinol; 2015 Sep; 413():202-8. PubMed ID: 26159901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies.
    Gu Y; Lewis DF; Wang Y
    J Clin Endocrinol Metab; 2008 Jan; 93(1):260-6. PubMed ID: 17956952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of anti-hypertensive drugs on production of soluble fms-like tyrosine kinase 1 and soluble endoglin from human normal and pre-eclamptic placentas in vitro.
    Xu B; Thornton C; Tooher J; Ogle R; Lim S; Makris A; Hennessy A
    Clin Exp Pharmacol Physiol; 2009 Aug; 36(8):839-42. PubMed ID: 19215236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.